{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:31:12Z","timestamp":1789594272744,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["TTK220324671"],"award-info":[{"award-number":["TTK220324671"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118633","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:07:32Z","timestamp":1759860452000},"page":"118633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: A comprehensive narrative review"],"prefix":"10.1016","volume":"192","author":[{"given":"Marilize","family":"Horn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontobeko","family":"Gumede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-1545","authenticated-orcid":false,"given":"Mlindeli","family":"Gamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118633_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.814209","article-title":"Non-Alcoholic fatty liver disease in HIV\/HBV patients \u2013 a metabolic imbalance aggravated by antiretroviral therapy and perpetuated by the Hepatokine\/Adipokine axis breakdown","volume":"13","author":"Iacob","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib4","first-page":"27","article-title":"Nonalcoholic fatty liver disease (NAFLD): a comprehensive review","volume":"36","author":"Salt","year":"2004","journal-title":"J. Insur Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11904-016-0330-z","article-title":"Metabolic complications and glucose metabolism in HIV infection: a review of the evidence","volume":"13","author":"Willig","year":"2016","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"24","key":"10.1016\/j.biopha.2025.118633_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415489","article-title":"Non-Alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118633_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S2468-1253(21)00275-2","article-title":"Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa","volume":"6","author":"Spearman","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1309\/RTPM1PY6YGBL2G2R","article-title":"Pathology of nonalcoholic fatty liver disease","volume":"128","author":"Yeh","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26072","article-title":"Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from subsaharan Africa","volume":"26","author":"Manzano-Nunez","year":"2023","journal-title":"J. Int AIDS Soc."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40121-018-0229-7","article-title":"A review of Non-Alcoholic fatty liver disease in HIV-Infected patients: the next big thing?","volume":"8","author":"van Welzen","year":"2019","journal-title":"Infect. Dis. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118633_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/v15122432","article-title":"Impact of combination antiretroviral treatment on liver metabolic health in HIV-Infected persons","volume":"15","author":"Bia\u0142y","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.aohep.2020.02.004","article-title":"Antiretroviral therapies for human immunodeficiency virus and liver disease: challenges and opportunities","volume":"19","author":"Abarca","year":"2020","journal-title":"Ann. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v14010122","article-title":"Impact of combined antiretroviral therapy on metabolic syndrome components in adult people living with HIV: a literature review","volume":"14","author":"Sapu\u0142a","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","article-title":"Resolving the paradox of hepatic insulin resistance","volume":"7","author":"Santoleri","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pr9010135","article-title":"Non-Alcoholic fatty liver disease: from pathogenesis to clinical impact","volume":"9","author":"Caturano","year":"2021","journal-title":"Processes"},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2025.118633_bib18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fgstr.2025.1506032","article-title":"Prevalence and risk factors of metabolic-associated fatty liver disease in sub-Saharan Africa: a systematic review and meta-analysis","volume":"4","author":"Sindato","year":"2025","journal-title":"Front. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib19","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021\u20132045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"issue":"7","key":"10.1016\/j.biopha.2025.118633_bib23","article-title":"Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants","volume":"6","author":"Bril","year":"2024","journal-title":"JHEP Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118633_bib25","article-title":"Metabolic Dysfunction\u2013Associated liver disease (MASLD) - hepatic and biliary disorders - MSD manual professional edition MSD manual professional version","author":"Tholey","year":"2025","journal-title":"@MSDManualPro"},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management","volume":"41","author":"Marjot","year":"2019","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.livres.2020.03.001","article-title":"Nuclear receptors and non-alcoholic fatty liver disease: an update","volume":"4","author":"Yang","year":"2020","journal-title":"Liver Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.118633_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/nu10101383","article-title":"Regulation and metabolic significance of de novo lipogenesis in adipose tissues","volume":"10","author":"Song","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014119","article-title":"Serial biomarkers of de novo lipogenesis fatty acids and incident heart failure in older adults: the cardiovascular health study","volume":"9","author":"Lee","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2025.118633_bib30","unstructured":"Adverse Effects of Antiretroviral Agents | NIH: Clinical info HIV.gov; 2024 [Available from: \u3008https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/adverse-effects-antiretroviral-agents\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib31","author":"National Institutes of H","year":"2024","journal-title":"Advers. Eff. Antiretrovir. Agents | NIH Clin. Info Hiv. Gov."},{"issue":"9","key":"10.1016\/j.biopha.2025.118633_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1043-2760(00)00323-4","article-title":"Free fatty acids and pathogenesis of type 2 diabetes mellitus","volume":"11","author":"Bergman","year":"2000","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent epidemiology and risk factors of nonalcoholic fatty liver disease","volume":"31","author":"Huh","year":"2022","journal-title":"J. Obes. Metab. Syndr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib34","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.1038\/sj.ejcn.1600744","article-title":"De novo lipogenesis in humans: metabolic and regulatory aspects","volume":"53","author":"Hellerstein","year":"1999","journal-title":"Eur. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10409231003667500","article-title":"Genetic control of de novo lipogenesis: role in diet-induced obesity","volume":"45","author":"Strable","year":"2010","journal-title":"Crit. Rev. Biochem Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118633_bib36","article-title":"Acetyl-CoA carboxylases and diseases","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118633_bib37","series-title":"An Innovative Approach to Understanding and Treating Cancer: Targeting pH","first-page":"15","article-title":"Chapter 2 - cancer metabolism","author":"Koltai","year":"2020"},{"key":"10.1016\/j.biopha.2025.118633_bib38","unstructured":"PubChem. Palmitic Acid National Library of Medicine2024 [Available from: \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Palmitic-Acid\u3009."},{"issue":"50","key":"10.1016\/j.biopha.2025.118633_bib39","doi-asserted-by":"crossref","first-page":"41914","DOI":"10.1074\/jbc.M112.418855","article-title":"Structural characterization of a unique interface between carbohydrate response Element-binding protein (ChREBP) and 14-3-3\u03b2 protein*","volume":"287","author":"Ge","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M081836","article-title":"Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice [S]","volume":"59","author":"Linden","year":"2018","journal-title":"J. Lipid Res"},{"issue":"8","key":"10.1016\/j.biopha.2025.118633_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151128","article-title":"Causative and sanative dynamicity of ChREBP in Hepato-Metabolic disorders","volume":"99","author":"Daniel","year":"2020","journal-title":"Eur. J. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","article-title":"A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism","volume":"6","author":"Fisher","year":"2017","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2025.118633_bib43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fgene.2019.00472","article-title":"Carbohydrate sensing through the transcription factor ChREBP","volume":"10","author":"Ortega-Prieto","year":"2019","journal-title":"Front Genet"},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib44","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI41636","article-title":"The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans","volume":"122","author":"Benhamed","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"9","key":"10.1016\/j.biopha.2025.118633_bib45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tibs.2018.01.005","article-title":"SREBPs in lipid metabolism, insulin signaling, and beyond","volume":"43","author":"DeBose-Boyd","year":"2018","journal-title":"Trends Biochem Sci."},{"issue":"8","key":"10.1016\/j.biopha.2025.118633_bib47","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver x receptors in lipid signalling and membrane homeostasis","volume":"14","author":"Wang","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118633_bib48","first-page":"736","article-title":"Liver x receptors (LXRs). part I: structure, function, regulation of activity, and role in lipid metabolism","volume":"61","author":"W\u00f3jcicka","year":"2007","journal-title":"Post. Hig. Med Dosw (Online)"},{"issue":"9","key":"10.1016\/j.biopha.2025.118633_bib49","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1128\/MCB.21.9.2991-3000.2001","article-title":"Identification of liver x receptor-retinoid x receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter","volume":"21","author":"Yoshikawa","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118633_bib50","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2010.11.053","article-title":"Liver x receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease","volume":"140","author":"Beaven","year":"2011","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1507\/endocrj.K07E-110","article-title":"ChREBP: a Glucose-activated transcription factor involved in the development of metabolic syndrome","volume":"55","author":"Iizuka","year":"2008","journal-title":"Endocr. J."},{"key":"10.1016\/j.biopha.2025.118633_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mito.2016.10.005","article-title":"Drug induced mitochondrial dysfunction: mechanisms and adverse clinical consequences","volume":"31","author":"Vuda","year":"2016","journal-title":"Mitochondrion"},{"issue":"10","key":"10.1016\/j.biopha.2025.118633_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/metabo9100233","article-title":"Mitochondrial dysfunction in the transition from NASH to HCC","volume":"9","author":"L\u00e9veill\u00e9","year":"2019","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cld.2013.07.012","article-title":"Drug-induced steatohepatitis","volume":"17","author":"Patel","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2025.118633_bib55","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Definition & Facts of NAFLD & NASH: NIH; 2024 [Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib56","unstructured":"Hoon Lee T., Nguyen M. Hepatic Fibrosis - Hepatic and Biliary Disorders - MSD Manual Professional Edition: @MSDManualPro; 2025 [updated Jan 2024. Available from: \u3008https:\/\/www.msdmanuals.com\/professional\/hepatic-and-biliary-disorders\/fibrosis-and-cirrhosis\/hepatic-fibrosis\u3009."},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib57","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/07853890802552437","article-title":"New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)","volume":"41","author":"Ali","year":"2009","journal-title":"Ann. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","author":"Tapper","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib60","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118633_bib62","unstructured":"WHO. HIV data and statistics: World Health Organization; 2023 [Available from: \u3008https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics#:\u223c:text=29.8%20million%20people%20living%20with%20HIV%20were%20receiving%20antiretroviral%20therapy%20globally\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib63","series-title":"South Africa - HIV country profile 2023","author":"WHO","year":"2023"},{"key":"10.1016\/j.biopha.2025.118633_bib64","unstructured":"WHO. Global HIV Programme: World Health Organization; 2024 [Available from: \u3008https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment#:\u223c:text=HIV%20treatment%20involves%20the%20use\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib65","series-title":"Treatment decisions for HIV: entire section","author":"U.S. Department of Veterans Affairs","year":"2019"},{"key":"10.1016\/j.biopha.2025.118633_bib66","unstructured":"Kara Mayer Robinson. Single-Tablet Treatment Regimen for HIV: WebMD; 2022 [Available from: \u3008https:\/\/www.webmd.com\/hiv-aids\/single-tablet-hiv\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/PPA.S28482","article-title":"Spillover adherence effects of fixed-dose combination HIV therapy","volume":"6","author":"Kauf","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.biopha.2025.118633_bib68","unstructured":"Philippe Le Mercier CHPM, Edouard de C. Non-Nucleoside Reverse Transcriptase Inhibitors \u223c ViralZone ViralZone 2024 [Available from: \u3008https:\/\/viralzone.expasy.org\/5179\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib69","unstructured":"Clinical Info HIVg. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) | NIH: Clinical info HIV.gov; 2024 [Available from: \u3008https:\/\/clinicalinfo.hiv.gov\/en\/glossary\/non-nucleoside-reverse-transcriptase-inhibitor-nnrti\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib70","unstructured":"Yee J., Preuss C.V. Efavirenz [Text]. StatPearls Publishing; 2023 [updated 2023\/03\/24. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib71","unstructured":"PubChem. Efavirenz National Library of Medicine2024 [Available from: \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Efavirenz\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib72","series-title":"Encyclopedia of Virology","first-page":"54","article-title":"ANTIVIRALS","author":"Field","year":"1999"},{"issue":"14","key":"10.1016\/j.biopha.2025.118633_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137180","article-title":"Leptin decreases de novo lipogenesis in patients with lipodystrophy","volume":"5","author":"Baykal","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib74","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib75","article-title":"Plasma efavirenz concentrations are associated with lipid and glucose concentrations","volume":"95","author":"Sinxadi","year":"2016","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.biopha.2025.118633_bib76","series-title":"Emtricitabine [Text]","author":"Muller","year":"2023"},{"key":"10.1016\/j.biopha.2025.118633_bib77","unstructured":"Livertox. Clinical and Research Infromation on Drug-Induced Liver Injury [Text]. National Institute of Diabetes and Digestive and Kidney Diseases; 2018 [updated 2018\/04\/26. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/\u3009."},{"key":"10.1016\/j.biopha.2025.118633_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110916","article-title":"Alteration of mitochondrial DNA homeostasis in drug-induced liver injury","volume":"135","author":"Fromenty","year":"2020","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063315","article-title":"Mitochondria as the target of hepatotoxicity and Drug-Induced liver injury: molecular mechanisms and detection methods","volume":"23","author":"Mihajlovic","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2025.118633_bib80","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir disoproxil fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2025.118633_bib81","series-title":"Biochemistry of Drug Metabolizing Enzymes","first-page":"125","article-title":"Chapter 5 - Drug-metabolizing enzymes and fate of prodrugs: from function to regulation","author":"Mallhi","year":"2022"},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib82","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11904-023-00669-7","article-title":"Fatty liver disease: enter the metabolic era","volume":"20","author":"Wegermann","year":"2023","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118633_bib83","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17849","article-title":"Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States","volume":"59","author":"Gawrieh","year":"2024","journal-title":"Aliment Pharm. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118633_bib84","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.3390\/v15122432","article-title":"Impact of combination antiretroviral treatment on liver metabolic health in HIV-Infected persons","volume":"15","author":"Bia\u0142y","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib85","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11739-025-03895-6","article-title":"Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030","volume":"20","author":"Huang","year":"2025","journal-title":"Intern Emerg. Med"},{"issue":"8","key":"10.1016\/j.biopha.2025.118633_bib86","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of Glucagon-Like Peptide-1 receptor agonists for the treatment of metabolic Dysfunction-Associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118633_bib87","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with metabolic Dysfunction-Associated steatotic liver disease: a systematic review and Meta-Analysis of randomized controlled trials","volume":"16","author":"Njei","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.biopha.2025.118633_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in Non-Alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70920","article-title":"Resmetirom: a breakthrough in the treatment of metabolic Dysfunction-Associated steatotic liver disease (MASLD)","volume":"8","author":"Shakeel","year":"2025","journal-title":"Health Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib90","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/hbsn-24-568","article-title":"Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease","volume":"13","author":"Lurje","year":"2024","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-025-00988-2","article-title":"Evolving role of GLP-1 therapies in liver disease","volume":"27","author":"Lindsay","year":"2025","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib92","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib93","article-title":"Metformin and fibrosis: a review of existing evidence and mechanisms","volume":"2021","author":"Wu","year":"2021","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2025.118633_bib94","first-page":"73","article-title":"Drug-induced liver injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol. Hepatol. Rev."},{"key":"10.1016\/j.biopha.2025.118633_bib95","series-title":"Drug-Induced hepatotoxicity [Text]. national library of Medicine","author":"Navarro","year":"2022"},{"key":"10.1016\/j.biopha.2025.118633_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104267","article-title":"Drug-induced liver steatosis in patients with HIV infection","volume":"145","author":"Gervasoni","year":"2019","journal-title":"Pharm. Res"},{"issue":"33","key":"10.1016\/j.biopha.2025.118633_bib97","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.3748\/wjg.v12.i33.5272","article-title":"Screening in liver disease","volume":"12","author":"Del Poggio","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118633_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101657","article-title":"Liver Function-How to screen and to diagnose: insights from personal experiences, controlled clinical studies and future perspectives","volume":"12","author":"Buechter","year":"2022","journal-title":"J. Pers. Med"},{"issue":"11","key":"10.1016\/j.biopha.2025.118633_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224706","article-title":"Conceptualising alcohol consumption in relation to long-term health conditions: exploring risk in interviewee accounts of drinking and taking medications","volume":"14","author":"Madden","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2025.118633_bib100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.15288\/jsad.2012.73.899","article-title":"Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases","volume":"73","author":"Grodensky","year":"2012","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.biopha.2025.118633_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119544","article-title":"Drug-induced liver injury and prospect of cytokine based therapy; a focus on IL-2 based therapies","volume":"278","author":"Kumar","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118633_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biomedicines11010015","article-title":"Treatment of Drug-Induced liver injury","volume":"11","author":"Teschke","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2025.118633_bib103","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ando.2023.05.002","article-title":"Metabolic complications of glucocorticoids \u2013 prevention by metformin","volume":"84","author":"Sanpawithayakul","year":"2023","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.biopha.2025.118633_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1327814","article-title":"Metformin: update on mechanisms of action on liver diseases","volume":"10","author":"Ruan","year":"2023","journal-title":"Front Nutr."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:24:13Z","timestamp":1775780653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":104,"alternative-id":["S0753332225008273"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118633","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: A comprehensive narrative review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118633"}}